Veldmar Therapeutics Ltd.
TSXV: VLDMPre-revenue oncology developer. Shares auditor and a scientific officer with Cascade BioSciences. Recently filed a bought-deal financing.
All filings
3 documents
| Filed | Type | Title | SEDAR+ ID |
|---|---|---|---|
| Jun 18, 2026 | News Release | Veldmar Closes $22M Bought-Deal Financing | SP-2026-06-18-VLDM-NR-44012 |
| May 22, 2026 | MD&A | Management's Discussion & Analysis — Q1 2026 | SP-2026-05-22-VLDM-MDA-44001 |
| Mar 27, 2026 | Annual Financial Statements | Audited Annual Financial Statements — Year ended December 31, 2025 | SP-2026-03-27-VLDM-AFS-43960 |
Filing calendar
| Type | Due | Filed | Status |
|---|---|---|---|
| Annual Financial Statements | Mar 31, 2026 | Mar 27, 2026 | on_time |
| Interim Financial Statements | May 30, 2026 | May 22, 2026 | on_time |